C21CM Supreme Court Brief, The Association for Molecular Pathology v. Myriad Genetics

…This case concerns whether material derived from human genes — isolated DNA — is patentable subject matter under Section 101 of the Patent Act. Amicus believes that efforts to undermine DNA sequence patents in the United States endanger this future by pushing inventors away from molecular diagnostics technology. Without their continued investment, private industry will no longer be able to subpport the same breadth of expensive and complex research, development, and commercialization of these critical health care products. This will cause serious harm to the well-being of patients who would otherwise benefit from personalized medicine. In view of amicus’s role in the genetic diagnostic field, it has a unique perspective on and keen interest in the question presented.

Clinical Laboratory Fee Schedule (CLFS) 2015 Public Meeting Comments

On behalf of the Coalition for 21st Century Medicine, and in follow-up to the comments we presented during the public meeting held on July 14, 2014, we are pleased to submit these additional comments for your consideration as you finalize your CY2015 Clinical Laboratory Fee Schedule (CLFS) Preliminary Payment Determinations.